ClinicalTrials.gg

Dry Eye Syndromes clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,369 studies for Dry Eye Syndromes across more than 10 countries. 209 are recruiting or about to start. 1,158 of them are mainly about Dry Eye Syndromes (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 3 narrower conditions too, such as Sjogren's Syndrome: 1,669 studies, 296 open.

ClinicalTrials.gov finds 1,724 studies for Dry Eye Syndromes. How that becomes 1,369 here

This page counts the studies the registry files under Dry Eye Syndromes, and those it files under no condition that list Dry Eye Syndromesthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 17, 2026. How condition pages count

  1. 1,724Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −294Filed under a narrower condition, counted on its own pageSjogren's Syndrome 267 · Keratoconjunctivitis Sicca 17 · Xerophthalmia 8
  3. −2List Dry Eye Syndromes as a condition, but the registry did not file them under itMost often written as “Moderate to Severe Dry Eye Syndrome” (1) and “Inflammatory Dry Eye Disease” (1). The registry filed them under other conditions only, most often Lymphoma, Follicular (1) and Hematologic Neoplasms (1).
  4. −59Match it another way15 name it in the title and 44 by a synonym or other text the search reads.
  5. 1,369The count on this page9 of them list Dry Eye Syndromes in their own words; the registry filed them under no condition.

Status

Completed
910
Status unknown
131
Recruiting
116
Not yet recruiting
84
Terminated
51
Withdrawn
32

Phase

Phase 2
228
Phase 4
220
Phase 3
179
Phase 1
76
Early Phase 1
16

Where

United States
544
China
106
Korea, Republic of
49
France
47
Canada
45
Italy
44

Who develops what

Add Dry Eye Syndromes to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 39 programs from 31 companies, 33 with this as their studies’ main aim; 4 with a live phase 3 study; 8 primary completions in the next 12 months. Compare AbbVie, Bausch Health Companies and Hoffmann-La Roche here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
Cyclosporine Ophthalmic EmulsionRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT05743764 · Huons Global · Phase 3 · comparator · “Restasis” · registered Feb 2023
  • NCT05733624 · SCAI Therapeutics · Phase 2 · comparator · “Restasis 0.05% eyedrop” · registered Feb 2023
  • NCT04127851 · Taejoon Pharmaceutical Co., Ltd. · Phase 4 · standard-care · “Cyclosporine Ophthalmic Emulsion 0.05% standard therapy (CMC 0.5% add)” · registered Oct 2019
  • NCT03597139 · Aurinia Pharmaceuticals Inc. · Phase 2 · comparator · “Restasis®” · registered Jul 2018
  • NCT03461575 · Huons Global · Phase 3 · comparator · “Restasis” · registered Mar 2018
AbbVie50% of its industry studies22 studies

7 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
licaminlimab☆ Track1 live phase-3 study: NCT07548632Oculis
Topical Fibrinogen-depleted Human Standardized Platelet Lysate CAM-101☆ Track1 live phase-3 study: NCT06903611Cambium Bio Limited
OT202☆ Track1 live phase-3 study: NCT07740564Ocumension Therapeutics (Suzhou) Co., Ltd
CsA-PG Ophthalmic Gel☆ Track1 live phase-3 study: NCT06942793Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.

The 4 in phase 3 with the nearest primary completion, of 39 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (8)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.fulipiftide, Lubricant Eye Drops · BRIM Biotechnology Inc. · Phase 2 named, not the main aimNCT07078955 A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease — primary endpoint: Change from baseline in total corneal fluorescein staining (tCFS) score · 99 enrolled
  • Dec 2026 est.licaminlimab · Oculis · Phase 3 main aimNCT07548632 A Clinical Study Evaluating Licaminlimab for Dry Eye Disease — primary endpoint: Change from baseline in global ocular discomfort severity score at Day 29 in participants with DED and specific TNFR1 genotype · 160 enrolled
  • 27 Dec 2026 est.DFL24498 · Dompé Farmaceutici S.p.A · Phase 2 main aimNCT07503886 An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease — primary endpoint: Change from baseline in corneal fluorescein staining (CFS) assessed by National Eye Institute (NEI) scale (0 to 15) in the Study Eye · 417 enrolled

5 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Dry Eye Syndromes studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Calcineurin inhibitors 5 open · Corticosteroids 1 open · Antihistamines 8 · Tyrosine kinase inhibitors (TKIs) 4

Coming up

83studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger. 7 (6%) take children under 18. 3 (3%) are for women only and 0 (0%) for men only; 29 (25%) take healthy volunteers.

Recruiting studies that take each age, of 116
AgeWomenMen
106 (5%)6 (5%)
1887 (75%)87 (75%)
30109 (94%)106 (91%)
40108 (93%)106 (91%)
50109 (94%)108 (93%)
65105 (91%)104 (90%)
7599 (85%)99 (85%)
8584 (72%)84 (72%)

Across all 1,369 studies, recruiting or not: 19% stop at 75 or younger and 12% at 65; 5% take children; 2% are for women only and <1% for men only; 27% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Dry Eye Syndromes studies take

Of 112 phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 12 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 16 mo4–13 · 34 studies——
Phase 1/214 mo7–24 · 21 studies——
Phase 27 mo5–12 · 91 studies7 mo4–11 · 75 studies—
Phase 2/311 mo6–18 · 15 studies——
Phase 310 mo7–15 · 96 studies9 mo6–15 · 81 studies—
Phase 412 mo5–23 · 112 studies8 mo4–15 · 28 studies13 mo7–28 · 84 studies
Interventional, no phase10 mo4–18 · 314 studies9 mo4–14 · 115 studies12 mo5–25 · 199 studies
Observational12 mo5–64 · 69 studies—21 mo9–64 · 53 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,369. Browse all 1,369 → or search them.